Partner Headlines - AMGN

  1. Gilead 2017 Outlook Hamstrung On Hep C, But RBC Bullish On Amgen, ...

    Investors Business Daily
  2. Lilly Regains Key Migraine Drug With $960 Million CoLucid Acquisition

    Investors Business Daily
  3. Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad

    Investors Business Daily
  4. Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink

    Investors Business Daily
  5. Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug ...

    Investors Business Daily
  6. Trump Says Drugmakers 'Getting Away With Murder', Cites F-35, ...

    Investors Business Daily
  7. Stocks Still Mixed, Medicals Lead Upside; Is Incyte The Next ...

    Investors Business Daily
  8. Calithera Pharma In Focus, Part 3 - Arginase Inhibitor And Acquisition ...

    TalkMarkets
  9. AskSlim Market Week - 01/06/17

    TalkMarkets
  10. Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?

    Investors Business Daily
  11. Regeneron, Sanofi Hammered After Judge Bans Amgen-Rivaling LDL-Buster

    Investors Business Daily
  12. Stock Futures Ease, Dollar Climbs; Early Risers: Amgen, Ionis, ...

    Investors Business Daily
  13. US Futures Flat Ahead Of December Payrolls; Dollar Rebounds

    TalkMarkets
  14. After Hours: Gap Gaps Up, Amgen Blocks Rival, Shake Shack Shakeup

    Investors Business Daily
  15. Regeneron, Sanofi LDL-Buster At Risk After Judge Upholds Amgen ...

    Investors Business Daily
  16. Morning Call For Wednesday, Jan. 4

    TalkMarkets
  17. Mean Reversion and The Bell Curve

    TalkMarkets
  18. Amgen Plans Robust 2017 In Alzheimer's, Migraines, Oncology: ...

    Investors Business Daily
  19. Merck (MRK) Does Well In 2016: Reasons For Outperformance

    TalkMarkets
  20. Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit ...

    Investors Business Daily
  21. Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit ...

    Investors Business Daily
  22. Gilead Is A Hail Mary: 3 Better Stocks To Consider

    TalkMarkets
  23. Regeneron Likely To Jump On Amgen LDL-Buster, But Expectations ...

    Investors Business Daily
  24. Morning Call For Tuesday, Dec. 20

    TalkMarkets
  25. Weighing the Week Ahead: New Year, New Highs, and a New List ...

    TalkMarkets
  26. Can GILD Stock Make A Comeback In 2017?

    TalkMarkets
  27. The FDA: Small-Cap Catalyst Or Small-Cap Killer?

    TalkMarkets
  28. Does The Symbolism Of Dow 20K Affect Technical Analysis?

    TalkMarkets
  29. Nvidia, KLA-Tencor Are Buys, Amgen An Outperform, Kroger Upgraded

    Investors Business Daily
  30. Biotechs Mixed Hurt By Alexion And Ophthotech

    TalkMarkets
  31. Johnson & Johnson Boosted By Barron's Call For Rally

    TalkMarkets
  32. Will Trump Break With Republicans And Push Major Drug Price Reform?

    Investors Business Daily
  33. Actelion Remains In M&A Spotlight, ASH Data In Focus

    TalkMarkets
  34. Trump Vow On Drug Prices Hammers Drug Stocks, But Key Indexes ...

    Investors Business Daily
  35. Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark ...

    Investors Business Daily
  36. Guide to American Funds Investment Company of America R2 Fund ...

    TalkMarkets
  37. Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap ...

    Investors Business Daily
  38. Here's How Much Trump Tax Cuts Could Boost The Stock Market

    Investors Business Daily
  39. Bluebird Rockets On Myeloma Drug; Celgene Gets Boost

    Investors Business Daily
  40. Bluebird Bio, Celgene Multiple Myeloma Therapy Shines In 9-Patient ...

    Investors Business Daily
  41. TalkMarkets Presents: Ranjit Thomas - An Overview Of Recent Earnings ...

    TalkMarkets
  42. 6 Worthy Dividend Stocks Down 10% Or More

    TalkMarkets
  43. Morning Call For Thursday, Nov. 17

    TalkMarkets
  44. Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved

    TalkMarkets
  45. Stock Exchange: Is Technical Analysis Effective Post-Election?

    TalkMarkets
  46. Stocks Going Ex Dividend The Third Week Of November

    TalkMarkets
  47. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets
  48. Rayno Biobeat #2…Good Value in Large Cap Biopharmaceuticals

    TalkMarkets
  49. Before The Move: Stocks To Own If Trump Wins

    TalkMarkets
  50. Pricing Issues Continue To Weigh On The Pharma Sector

    TalkMarkets
  51. Fundamentals Remain Strong In The Pharma Sector

    TalkMarkets
  52. Biotech Meltdown: Financial Metrics Offer Few Clues For What ...

    TalkMarkets
  53. Why After A Massive Run, CoLucid Shares Still Look Attractive ...

    TalkMarkets
  54. The U.S. Economy Grew At Its Fastest Pace In Two Years

    TalkMarkets
  55. AskSlim Market Week - 10/28/16

    TalkMarkets
  56. Gilead Sciences, Inc.: Why You Should Go Long On Gilead Stock?

    TalkMarkets
  57. 5 Stocks To Watch After The Market Closes Today - October 27, ...

    TalkMarkets
  58. 5 Stocks To Watch After The Market Closes Today, 10/27/16

    TalkMarkets
  59. Biotech Bear Market Looking For Relief From Q3 Large Cap Growth

    TalkMarkets
  60. Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex ...

    TalkMarkets
  61. 5 Healthcare Stocks To Buy Despite A Clinton Victory

    TalkMarkets
  62. Novartis Tops Q3 Earnings, Misses Sales Estimates

    TalkMarkets
  63. 7 Drug Stocks To Consider As Biosimilars Pick Up Pace

    TalkMarkets
  64. Swing Trading Watch List - October 11, 2016

    TalkMarkets
  65. Earnings ESP

    TalkMarkets
  66. Rayno 2016 Life Science Portfolio Update

    TalkMarkets
  67. Ligand Pharma Dives After Out-Licensed Drug Misses Study Goal

    TalkMarkets
  68. Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster ...

    IBD
  69. Biosimilars In Limelight On FDA Approval Of Amgen Drug

    TalkMarkets
  70. Stocks Extend Gains; Facebook Up On Positive Analyst Chatter

    IBD
  71. Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest ...

    IBD
  72. Biotech ETFs Lead Q3 Rally: XBI Breaks Out

    TalkMarkets
  73. 2 Biotech Funds Leading Nascent Bull Market: Which Is Right For ...

    Investors Business Daily
  74. QQQ ETF Posts 52-Week High; Energy Stocks Sag As Oil Drops To ...

    Investors Business Daily
  75. What's Driving The Biotech Stock Rally? And Will It Last?

    Investors Business Daily
  76. Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch ...

    Investors Business Daily
  77. Apple, Facebook, Alphabet, Amazon, Ford, McDonald's Headline ...

    Investors Business Daily
  78. Amgen Beats Q2 Earnings Estimates, Raises Guidance

    Investors Business Daily
  79. Facebook, GoPro, Amgen Beat; Whole Foods Disappoints

    Investors Business Daily
  80. Nasdaq Up As Fed Stands Pat On Rates; Will Apple Break Its Downtrend?

    Investors Business Daily
  81. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily
  82. This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or ...

    Investors Business Daily
  83. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, ...

    Investors Business Daily
  84. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  85. Chardan Upgrades Regeneron Amid Relative Underperformance To ...

    Benzinga
  86. Gilead, Johnson & Johnson or Roche?

    GuruFocus
  87. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga
  88. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement ...

    Benzinga
  89. The Generic Drug Battle

    Benzinga
  90. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD
  91. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, ...

    Benzinga
  92. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga
  93. Leerink Is Back On Board The Biotech Train

    Benzinga
  94. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD
  95. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus
  96. Maybe Some Good News For A Big Biotech ETF

    Benzinga
  97. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga
  98. Earnings Recap For January 28

    Benzinga
  99. FDA Accepts Amgen's Biosimilar Biologics License Application ...

    Benzinga
  100. Regeneron Is Now A Sell For Chardan

    Benzinga
Trading Center